Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ampligen after FOLFIRINOX for locally advanced pancreatic adenocarcinoma
2024-518627-29-00Phase 2Authorised
- Sponsor
- AIM ImmunoTech
- Start
- Dec 2024
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of rintatolimod in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by AIM ImmunoTech. Primary endpoint: Progression-free survival. Planned start Dec 2024; status: authorised.
02
Drugs
rintatolimod
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-518627-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518627-29-00.